NCT07091747 · Phase 1 · ACTIVE NOT RECRUITING
Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase
This Phase 1 trial is testing a cannabis-based product containing CBD and THC in people already diagnosed with Alzheimer's disease. Researchers want to see how the cannabinoids affect symptoms and certain biological markers. Phase 1 means this is early-stage work focused on safety and dosing. This particular stage is open-label, meaning all participants know they are receiving the extract. Details on full outcomes are limited so far.
You may qualify if
- Have participated in and completed all assessments conducted in the first phase of the project.
- Agree to and sign a new informed consent form.
You're excluded if
- Patients who did not participate in the first stage.
- Patients who began participating in the first stage but withdrew at any time.
- Patients who do not agree and/or fail to sign the new informed consent form
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-08-12